Corrections

GENETICS. For the article "Profound misregulation of muscle-specific gene expression in facioscapulohumeral muscular dystrophy" by Rossella Tupler, Giovanni Perini, Maria Antonietta Pellegrino, and Michael R. Green, which appeared in number 22, October 26, 1999, of *Proc. Natl. Acad. Sci. USA* (**96,** 12650–12654), GenBank accession nos. AW0055750–69 should read AW055750–69.

IMMUNOLOGY. For the article "CD4$^+$ T cells eliminate MHC class II-negative cancer cells *in vivo* by indirect effects of IFN-γ" by Dominik Mumberg, Paul A. Monach, Sherry Wanderling, Mary Philip, Alicia Y. Toledano, Robert D. Schreiber, and Hans Schreiber, which appeared in number 15, July 20, 1999, of *Proc. Natl. Acad. Sci. USA* (**96,** 8633–8638), the authors note the following change. In Table 4, due to a printer's error, the last entry in the third column was incorrectly entered as 2/12. The correct entry is 2/2. A corrected Table 4 is shown below.

Table 4. LNC from mL9-immunized mice reject tumor cells made insensitive to IFN-γ (PRO-DNγR), but still require IFN-γ for this effect

LNC*	Antibody treatment[†]	Tumor incidence after 28 days[‡]
−	−	5/5
+	−	0/5
+	Anti-IFN-γ	2/2

*SCID mice were inoculated s.c. with PRO-DNγR tumor cells and received LNC from mL9-immunized mice.

[†]An additional animal treated with LNC and also with anti-IL-4 antibody rejected the tumor cell challenge similar to the LNC-treated mice treated with anti-IL-4 in Table 3.

[‡]The tumor incidence of PRO-DNγR for LNC-treated versus untreated mice was statistically significant (*P* value = 0.008) by Fisher's Exact test. The difference between tumor incidence for LNC-treated and LNC-treated plus anti-IFN-γ antibody is also statistically significant (*P* value = .048) by Fisher's Exact test.

CORRECTIONS